Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract win valued at £119,000 for model-informed drug development (“MIDD”) modelling, incorporating pharmacokinetic/pharmacodynamic (“PK/PD”) modelling.   The Company also announces that it has entered into non-binding heads of terms with a third party, whose identity is not being...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its audited results for its financial year ended 30 June 2026 and to give notice of its Annual General Meeting ("AGM").   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has secured new contracts with a combined value of more than £205,000.   The new awards comprise work across the Company's complementary service lines and provide further evidence of strengthening demand for Physiomics' specialist capabilities.   Together with the contract...

TR-1: Standard form for notification of major holdings   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that it was notified on 20 August 2026 by Robert McFadden that as of 18 August 2026 he holds 13,678,940 ordinary shares of 0.4 pence each in the Company representing 3.02% of the Company's issued share capital, following a market purchase at...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the Company, has acquired, via market purchases, 1,111,111 new ordinary shares of 0.4p in the Company ("Ordinary Shares") at a price of 0.45p per Ordinary Share.   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Mike Whitlow, Director of the Company, has acquired, via market purchases, 3,000,000 new ordinary shares of 0.4p in the Company ("Ordinary Shares") at a price of 0.45p per Ordinary Share.   Click here to read in full  ...

TR-1: Standard form for notification of major holdings   Click here to read in full....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has secured multiple contract awards with a combined estimated value in excess of £200,000.   The awards comprise a combination of follow-on engagements within the Company's Biometrics service line and a new contract within its Modelling & Simulation...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the promotion of Jesse Thissen to the position of Chief Operating Officer (COO) with immediate effect.   Jesse has served as Head of Biometrics and has played an instrumental role in strengthening the Company's operational capabilities, technical leadership and project...